Chief Executive Officer
David is a life sciences veteran with three decades of leadership experience building businesses and teams to rapidly scale from initial launch to annual revenues of $300M. David graduated from Sheffield University in the UK with an advanced degree in Applied Statistics.
Chief Financial Officer
James Bendle is a versatile finance professional with experience in pre-IPO and large companies. Bendle has led teams in Finance, Investment, Pricing, Treasury, FP&A, M&A analysis, and Reporting functions for companies from startup to Fortune 50. His specialties include FP&A, business planning, modeling, investments, partnerships and scaling operations and systems.
Tricia D’Cruz is an experienced senior executive, strategy consultant, and entrepreneur. For more than three decades, she has been a leader in growing high-tech companies. Ms. D’Cruz has the distinction of success at both large multi-national public companies and early-stage startup ventures, with extensive experience in mergers and acquisitions.
Chief Marketing Officer
Michele Hodde is an entrepreneurial-minded marketing executive who drives top- and bottom-line results by creating and executing winning strategies and building great products, companies, and teams from start-ups to global enterprises. Specialties include identifying unrealized market opportunities, positioning and segmentation, and implementing processes and systems for growth.
Mark Kunitomi, Ph.D
Chief Scientific Officer
Mark Kunitomi was a post-doctoral fellow at UC San Francisco with a background in genomics, bioinformatics and microbiology. He has a Ph.D. in Biochemistry & Molecular Biology from the University of California, San Francisco.
David Chambliss, Ph.D
Chief Technology Officer
David Chambliss brings deep technical expertise with a background in application of cloud-based tools to bacterial genomics & metagenomic analysis. He has a Ph.D. in Applied Physics from Cornell University.
VP, Head of Business Development
Ellen Gordon has worked for more than two decades on behalf of pharmaceutical and biotech companies to analyze data and answer key business questions across the product life cycle, focusing on drug-target and biomarker discovery as well as early-stage development. She holds a bachelor’s from Brandeis University, a master’s from Georgetown University, and a Ph.D. in Political Science from the University of Michigan.